Published in J Med Virol on October 01, 1987
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol (1992) 1.95
Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc Natl Acad Sci U S A (1989) 1.57
HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly. Nat Microbiol (2017) 1.37
Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect Immun (1994) 1.31
Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol (1997) 1.27
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol (2006) 0.96
Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol (2001) 0.90
Murine immune response to HIV-1 p24 core protein following subcutaneous, intraperitoneal and intravenous immunization. Immunology (1991) 0.80
Chimeric Rabbit/Human Fab Antibodies Against the Hepatitis B e-antigen and Their Potential Applications in Assay, Characterization and Therapy. J Biol Chem (2017) 0.75
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
Molecular cloning of the DNA ligase gene from bacteriophage T4. II. Amplification and preparation of the gene product. J Mol Biol (1979) 5.86
The hepatitis delta (delta) virus possesses a circular RNA. Nature (1986) 4.00
Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci U S A (1993) 3.99
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol (1993) 3.68
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Suppression of malignancy and differentiation in melanotic melanoma cells. Proc Natl Acad Sci U S A (1970) 2.44
The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. J Gen Virol (1986) 2.29
Dietary calcium, physical activity, and risk of hip fracture: a prospective study. BMJ (1989) 2.24
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis. Proc Natl Acad Sci U S A (1982) 2.19
Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) (1993) 2.12
Specific complex of human immunodeficiency virus type 1 rev and nucleolar B23 proteins: dissociation by the Rev response element. Mol Cell Biol (1991) 2.02
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure. J Virol (1990) 1.94
Anisotropic rotational diffusion of perdeuterated HIV protease from 15N NMR relaxation measurements at two magnetic fields. J Biomol NMR (1996) 1.94
Comparative immunogenicity of hepatitis B virus core and E antigens. J Immunol (1988) 1.92
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol (1995) 1.63
Isolation and characterization of two sequence-specific endonucleases from Anabaena variabilis. Biochem J (1976) 1.62
Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. J Immunol Methods (1985) 1.62
Cloning and expression of a cDNA for human thioredoxin. J Biol Chem (1988) 1.55
Hepatitis B virus antigens made in microbial cells immunise against viral infection. EMBO J (1984) 1.54
Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology (1989) 1.47
Cloning and expression of the chromosomal immune interferon gene of the rat. EMBO J (1985) 1.47
Oestrogen status in relation to the early training responses in human thumb adductor muscles. Acta Physiol (Oxf) (2006) 1.46
Hazelnut allergy differs between children and adults in frequency of severity, aetiology and relevance of diagnostic parameters. Clin Exp Allergy (2014) 1.41
[Pulmonary infection with Coccidioides immitis]. Ned Tijdschr Geneeskd (1996) 1.39
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci U S A (1990) 1.39
[Neurological complications of infectious mononucleosis in 3 patients]. Ned Tijdschr Geneeskd (1994) 1.37
The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther (2011) 1.32
Purification and characterization of human interleukin-1 alpha produced in Escherichia coli. Eur J Biochem (1987) 1.28
Tumour necrosis factor is a compact trimer. FEBS Lett (1987) 1.26
Rabbit IL-1. Cloning, expression, biologic properties, and transcription during endotoxemia. J Immunol (1989) 1.26
Three-dimensional structure of ubiquinol:cytochrome c reductase from Neurospora mitochondria determined by electron microscopy of membrane crystals. J Mol Biol (1981) 1.26
A recombinant Chinese hamster ovary cell line containing a 300-fold amplified tetramer of the hepatitis B genome together with a double selection marker expresses high levels of viral protein. J Mol Biol (1986) 1.23
Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase. J Biol Chem (1994) 1.22
In mice, the muscle weakness due to age is absent during stretching. J Physiol (1991) 1.19
Measurement of 3hJNC' connectivities across hydrogen bonds in a 30 kDa protein. J Biomol NMR (1999) 1.17
Three-dimensional solution structure of the HIV-1 protease complexed with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic resonance spectroscopy. Protein Sci (1996) 1.16
Production of immunologically active surface antigens of hepatitis B virus by Escherichia coli. Proc Natl Acad Sci U S A (1981) 1.16
Biochemical and biological comparison of HIV-1 NEF and ras gene products. Virology (1991) 1.16
Cytokines and the immune response. Biotherapy (1996) 1.15
Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women. Clin Sci (Lond) (1999) 1.14
Isolation and characterization of monoclonal antibodies directed to rat interferon-gamma. Lymphokine Res (1989) 1.13
Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals (2011) 1.12
Induction of natural killer cell activity and allocytotoxicity in human peripheral blood lymphocytes after mixed lymphocyte culture. Scand J Immunol (1981) 1.10
Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. J Immunol (1989) 1.09
[Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis]. Ned Tijdschr Geneeskd (1993) 1.06
Membrane crystals of ubiquinone:cytochrome c reductase from Neurospora mitochondria. Nature (1979) 1.06
Conformation, stability, and folding of interleukin 1 beta. Biochemistry (1987) 1.05
Changes in maximal voluntary force of human adductor pollicis muscle during the menstrual cycle. J Physiol (1996) 1.04
Monomer-trimer equilibrium of the ectodomain of SIV gp41: insight into the mechanism of peptide inhibition of HIV infection. Protein Sci (1999) 1.02
Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet (1980) 1.02
Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther (2010) 1.01
Cloning, expression, and purification of rat IFN-gamma. Methods Enzymol (1986) 1.00
The weakness of old age is not due to failure of muscle activation. J Gerontol (1992) 1.00
Antiviral effect of interferon in vivo may be mediated by the host. Nature (1979) 1.00
C-terminal peptide identification by fast atom bombardment mass spectrometry. Biochem J (1988) 0.99
Mechanism of escape of exoerythrocytic forms (EEF) of malaria parasites from the inhibitory effects of interferon-gamma. J Immunol (1987) 0.99
Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci U S A (1986) 0.99
Hybridization of two biochemically marked human cell lines. Proc Natl Acad Sci U S A (1969) 0.99
Production and initial characterization of rat interferon. J Gen Virol (1980) 0.98
Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells. J Gen Virol (1991) 0.97
Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol (1983) 0.96
Iatrogenic meningitis by Streptococcus salivarius following lumbar puncture. J Hosp Infect (1995) 0.96
Characterization of human and mouse granulocyte-macrophage-colony-stimulating factors derived from Escherichia coli. Biochem J (1987) 0.95
Tumor necrosis factor inhibitor: purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities. Eur J Immunol (1990) 0.94
Simple method for measuring growth inhibition by interferon of cells in monolayer. J Virol Methods (1980) 0.94
Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. Cancer Res (1978) 0.93
Impact of class II major histocompatibility complex antigen expression on the immunogenic potential of isolated rat vascular endothelial cells. Transplantation (1987) 0.92
Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Exp Parasitol (1990) 0.91
Structure and expression in Escherichia coli of a cloned rat interferon-alpha gene. Nucleic Acids Res (1984) 0.91
Longitudinal analysis of hepatitis C virus infection and genetic drift of the hypervariable region. J Infect Dis (1994) 0.91
Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. Clin Exp Immunol (1989) 0.90
In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Clin Exp Immunol (1993) 0.90
Cloning and nucleotide sequence of the Salmonella typhimurium pepM gene. Mol Gen Genet (1990) 0.88
In vitro senescence of Syrian hamster mesenchymal cells of fetal to aged adult origin. Inverse relationship between in vivo donor age and in vitro proliferative capacity. Mech Ageing Dev (1986) 0.88
The successful medical management of gastric outflow obstruction associated with the use of non-steroidal anti-inflammatory drugs in the elderly. Postgrad Med J (1991) 0.88
Regular prescribing in a residential home for elderly women. Br Med J (Clin Res Ed) (1982) 0.88
Phenotypic and functional parameters of cellular immunity in a chimpanzee with a naturally acquired simian immunodeficiency virus infection. J Infect Dis (1995) 0.87
Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy (1997) 0.87
Point mutations of human interleukin-1 with decreased receptor binding affinity. FEBS Lett (1986) 0.87
A sensitive two-site enzyme immunoassay for the detection of rat interferon-gamma in biological fluids. J Interferon Res (1990) 0.86
The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) (2003) 0.86
Antagonistic effects of gamma interferon and steroids on tissue antigenicity. J Exp Med (1986) 0.86
Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int J Cancer (1983) 0.86
Heart rate and its variability change after the menopause. Exp Physiol (2000) 0.85
Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet (1977) 0.85
The value of non-human primates in the development of monoclonal antibodies. Nat Biotechnol (2013) 0.85
Negative control of hemoglobin production in somatic cell hybrids due to heme deficiency. Proc Natl Acad Sci U S A (1978) 0.85
Rat cytomegalovirus: induction of and sensitivity to interferon. Antiviral Res (1983) 0.85
Chemical inactivation of hepatitis B virus: the effect of disinfectants on virus-associated DNA polymerase activity, morphology and infectivity. J Virol Methods (1983) 0.85